You are here : Home > First Annual Report of PASREL-Imagerie

News | Tools & research instruments | Health & life sciences | Diagnosis and innovative treatment

First Annual Report of PASREL-Imagerie


PASREL-Imagerie publishes its first annual report, covering the years 2021 to 2024. Bringing together four research entities of CEA Paris-Saclay—IDMIT and MIRCen from CEA-Jacob, and NeuroSpin and SHFJ from CEA-Joliot— PASREL-Imagerie offers exceptional imaging capabilities in support of industrial innovation in health. Its annual report provides an opportunity to highlight its missions, achievements, and innovations.

Published on 10 February 2025

PASREL-Imagerie was created with the aim of opening the imaging research core facilities of the CEA-Jacob (MIRCen and IDMIT) and CEA-Joliot (NeuroSpin and SHFJ) institutes  to pharmaceutical companies, in order to support, accelerate, and de-risk their diagnostic and therapeutic innovations. It provides cutting-edge expertise and translational imaging platforms, including PET, MRI, ultrasound, multimodal imaging, and radiopharmaceutical production.

Since receiving funding under the French State and Île-de-France Region SESAME FILIÈRE PIA program, four years have passed—four years dedicated to structuring the ecosystem, fostering the imaging community, and adopting a forward-looking approach to better understand industry expectations and develop targeted collaborations.

All these achievements are presented in PASREL-Imagerie’s first activity report, published on February 5.

Top page